{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:33:02Z","timestamp":1790969582714,"version":"4.1.0"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The skeleton is a major site of breast cancer metastases. High bone turnover increases risk of disease progression and death. However, there is no direct evidence that high bone turnover is causally associated with the establishment and progression of metastases. In this study, we investigate the effects of high bone turnover in a model of breast cancer growth in bone. Female nude mice commenced a diet containing normal (0.6%; \u2018Normal-Ca\u2019) or low (0.1%; \u2018Low-Ca\u2019) calcium content. Mice were concurrently treated with vehicle or osteoprotegerin (1 mg\/kg\/d s.c; n = 16 per group). Three days later (day 0), 50,000 Tx-SA cells (variant of MDA-MB-231 cells) were implanted by intratibial injection. On day 0, mice receiving Low-Ca had increased serum parathyroid hormone (PTH) and tartrate-resistant acid phosphatase 5b levels, indicating secondary hyperparathyroidism and high bone turnover, which was maintained until day 17. Osteoprotegerin increased serum PTH but profoundly reduced bone resorption. On day 17, in mice receiving Low-Ca alone, lytic lesion area, tumor area, and cancer cell proliferation increased by 43%, 24%, and 24%, respectively, compared with mice receiving Normal Ca (P &amp;lt; 0.01). Osteoprotegerin treatment completely inhibited lytic lesions, reduced tumor area, decreased cancer cell proliferation, and increased cancer cell apoptosis. Increased bone turnover, due to dietary calcium deficiency, promotes tumor growth in bone, independent of the action of PTH. Breast cancer patients frequently have low dietary calcium intake and high bone turnover. Treatment to correct calcium insufficiency and\/or treatment with antiresorptive agents, such as osteoprotegerin, may be of benefit in the adjuvant as well as palliative setting. [Cancer Res 2007;67(17):9542\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1046","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T15:03:18Z","timestamp":1191250998000},"page":"9542-9548","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone"],"prefix":"10.1158","volume":"67","author":[{"given":"Yu","family":"Zheng","sequence":"first","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.K.","family":"Modzelewski","sequence":"additional","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kalak","sequence":"additional","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Blair","sequence":"additional","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Seibel","sequence":"additional","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R.","family":"Dunstan","sequence":"additional","affiliation":[{"name":"Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"2022061623241582500_B1","doi-asserted-by":"crossref","unstructured":"Coleman RE. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev\u20082001; 27: 165\u201376.","DOI":"10.1053\/ctrv.2000.0210"},{"key":"2022061623241582500_B2","doi-asserted-by":"crossref","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med\u20082004; 350: 1655\u201364.","DOI":"10.1056\/NEJMra030831"},{"key":"2022061623241582500_B3","doi-asserted-by":"crossref","unstructured":"Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL, and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol\u20082006; 3: 41\u20139.","DOI":"10.1038\/ncponc0381"},{"key":"2022061623241582500_B4","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer\u20082002; 2: 584\u201393.","DOI":"10.1038\/nrc867"},{"key":"2022061623241582500_B5","unstructured":"Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res\u20082001; 61: 4418\u201324."},{"key":"2022061623241582500_B6","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res\u20082001; 61: 4432\u20136."},{"key":"2022061623241582500_B7","doi-asserted-by":"crossref","unstructured":"Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer\u20082003; 107: 468\u201377.","DOI":"10.1002\/ijc.11397"},{"key":"2022061623241582500_B8","doi-asserted-by":"crossref","unstructured":"Zheng Y, Zhou H, Brennan K, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone\u20082007; 40: 471\u20138.","DOI":"10.1016\/j.bone.2006.09.016"},{"key":"2022061623241582500_B9","unstructured":"Diel IJ, Solomayer EF, Seibel MJ, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res\u20081999; 5: 3914\u20139."},{"key":"2022061623241582500_B10","doi-asserted-by":"crossref","unstructured":"Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer\u20082003; 89: 2031\u20137.","DOI":"10.1038\/sj.bjc.6601437"},{"key":"2022061623241582500_B11","doi-asserted-by":"crossref","unstructured":"Ali SM, Demers LM, Leitzel K, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol\u20082004; 15: 455\u20139.","DOI":"10.1093\/annonc\/mdh089"},{"key":"2022061623241582500_B12","doi-asserted-by":"crossref","unstructured":"Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst\u20082005; 97: 59\u201369.","DOI":"10.1093\/jnci\/dji002"},{"key":"2022061623241582500_B13","doi-asserted-by":"crossref","unstructured":"Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res\u20082006; 12: 3361\u20137.","DOI":"10.1158\/1078-0432.CCR-06-0269"},{"key":"2022061623241582500_B14","doi-asserted-by":"crossref","unstructured":"Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol\u20082005; 23: 4925\u201335.","DOI":"10.1200\/JCO.2005.06.091"},{"key":"2022061623241582500_B15","doi-asserted-by":"crossref","unstructured":"Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol\u20082005; 2: 504\u201317; quiz 501 p following 533.","DOI":"10.1038\/ncponc0320"},{"key":"2022061623241582500_B16","doi-asserted-by":"crossref","unstructured":"Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev\u20082001; 22: 477\u2013501.","DOI":"10.1210\/edrv.22.4.0437"},{"key":"2022061623241582500_B17","doi-asserted-by":"crossref","unstructured":"Harris SS, Soteriades E, Dawson-Hughes B. Secondary hyperparathyroidism and bone turnover in elderly blacks and whites. J Clin Endocrinol Metab\u20082001; 86: 3801\u20134.","DOI":"10.1210\/jcem.86.8.7783"},{"key":"2022061623241582500_B18","doi-asserted-by":"crossref","unstructured":"Scharla SH, Scheidt-Nave C, Leidig G, et al. Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study. Exp Clin Endocrinol Diabetes\u20081996; 104: 289\u201392.","DOI":"10.1055\/s-0029-1211456"},{"key":"2022061623241582500_B19","doi-asserted-by":"crossref","unstructured":"Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res\u20082001; 16: 1486\u201395.","DOI":"10.1359\/jbmr.2001.16.8.1486"},{"key":"2022061623241582500_B20","doi-asserted-by":"crossref","unstructured":"Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood\u20081997; 90: 3743\u201350.","DOI":"10.1182\/blood.V90.9.3743"},{"key":"2022061623241582500_B21","doi-asserted-by":"crossref","unstructured":"Woitge HW, Pecherstorfer M, Horn E, et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer\u20082001; 84: 344\u201351.","DOI":"10.1054\/bjoc.2000.1614"},{"key":"2022061623241582500_B22","doi-asserted-by":"crossref","unstructured":"Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem\u20082001; 47: 686\u201393.","DOI":"10.1093\/clinchem\/47.4.686"},{"key":"2022061623241582500_B23","doi-asserted-by":"crossref","unstructured":"Wolinsky I, Guggenheim K. Effect of low calcium diet on bone and calcium metabolism in rats and mice\u2014a differential species response. Comp Biochem Physiol Part A Physiol\u20081974; 49: 183\u201395.","DOI":"10.1016\/0300-9629(74)90554-4"},{"key":"2022061623241582500_B24","doi-asserted-by":"crossref","unstructured":"Ornoy A, Wolinsky I, Guggenheim K. Structure of long bones of rats and mice fed a low calcium diet. Calcif Tissue Res\u20081974; 15: 71\u20136.","DOI":"10.1007\/BF02059044"},{"key":"2022061623241582500_B25","doi-asserted-by":"crossref","unstructured":"Antic VN, Fleisch H, Muhlbauer RC. Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet. Calcif Tissue Int\u20081996; 58: 443\u20138.","DOI":"10.1007\/BF02509445"},{"key":"2022061623241582500_B26","unstructured":"Chen H, Hayakawa D, Emura S, Ozawa Y, Okumura T, Shoumura S. Effect of low or high dietary calcium on the morphology of the rat femur. Histol Histopathol\u20082002; 17: 1129\u201335."},{"key":"2022061623241582500_B27","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell\u20081997; 89: 309\u201319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"2022061623241582500_B28","doi-asserted-by":"crossref","unstructured":"Price JT, Quinn JMW, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res\u20082005; 65: 4929\u201338.","DOI":"10.1158\/0008-5472.CAN-04-4458"},{"key":"2022061623241582500_B29","doi-asserted-by":"crossref","unstructured":"Libouban H, Moreau MF, Basle MF, Bataille R, Chappard D. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone\u20082003; 33: 283\u201392.","DOI":"10.1016\/S8756-3282(03)00196-0"},{"key":"2022061623241582500_B30","doi-asserted-by":"crossref","unstructured":"Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis\u20082004; 21: 381\u20137.","DOI":"10.1007\/s10585-004-2869-0"},{"key":"2022061623241582500_B31","doi-asserted-by":"crossref","unstructured":"Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer\u20082000; 88: 2892\u20138.","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y"},{"key":"2022061623241582500_B32","doi-asserted-by":"crossref","unstructured":"Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun\u20082005; 328: 679\u201387.","DOI":"10.1016\/j.bbrc.2004.11.070"},{"key":"2022061623241582500_B33","doi-asserted-by":"crossref","unstructured":"Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res\u20081982; 4: 1\u20136.","DOI":"10.1016\/0221-8747(82)90002-9"},{"key":"2022061623241582500_B34","doi-asserted-by":"crossref","unstructured":"Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med\u20081992; 327: 1637\u201342.","DOI":"10.1056\/NEJM199212033272305"},{"key":"2022061623241582500_B35","doi-asserted-by":"crossref","unstructured":"McKane WR, Khosla S, Egan KS, Robins SP, Burritt MF, Riggs BL. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab\u20081996; 81: 1699\u2013703.","DOI":"10.1210\/jcem.81.5.8626819"},{"key":"2022061623241582500_B36","doi-asserted-by":"crossref","unstructured":"Saleh F, Jorde R, Sundsfjord J, Haug E, Figenschau Y. Causes of secondary hyperparathyroidism in a healthy population: the Tromso study. J Bone Miner Metab\u20082006; 24: 58\u201364.","DOI":"10.1007\/s00774-005-0647-y"},{"key":"2022061623241582500_B37","doi-asserted-by":"crossref","unstructured":"McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporos Int\u20081998; 8 Suppl 2: S3\u20136.","DOI":"10.1007\/PL00022725"},{"key":"2022061623241582500_B38","doi-asserted-by":"crossref","unstructured":"Giusti A, Barone A, Razzano M, et al. High prevalence of secondary hyperparathyroidism due to hypovitaminosis D in hospitalized elderly with and without hip fracture. J Endocrinol Invest\u20082006; 29: 809\u201313.","DOI":"10.1007\/BF03347375"},{"key":"2022061623241582500_B39","doi-asserted-by":"crossref","unstructured":"Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med\u20081983; 309: 1405\u20137.","DOI":"10.1056\/NEJM198312083092301"},{"key":"2022061623241582500_B40","doi-asserted-by":"crossref","unstructured":"Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol\u20082007; 18: 581\u201392.","DOI":"10.1093\/annonc\/mdl498"},{"key":"2022061623241582500_B41","doi-asserted-by":"crossref","unstructured":"Deapen D, Liu L, Perkins C, Bernstein L, Ross RK. Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer\u20082002; 99: 747\u201350.","DOI":"10.1002\/ijc.10415"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/19\/9542\/2573150\/9542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/19\/9542\/2573150\/9542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:33:58Z","timestamp":1655422438000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/19\/9542\/533466\/Accelerated-Bone-Resorption-Due-to-Dietary-Calcium"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":41,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2007,10,1]]},"published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1046","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1091432.545886","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}